Bayer, Orion win speedy approval for prostate cancer drug darolutamide

Three months ahead of schedule, Bayer and Finnish partner Orion’s prostate cancer drug darolutamide has been cleared for use by the US regulator under priority review. The androgen receptor (AR) inhibitor will be marketed as Nubeqa, and it was approved for patients with castration-resistant prostate cancer that has not spread to other parts of the body (nmCRPC).